INFINITY PHARMACEUTICALS, INC.
INFINITY PHARMACEUTICALS, INC. (INFI): 2 pipeline candidates · ~7 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.9 months
D/E -1.57 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for INFINITY PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$17.9M
Quarterly Burn
$8.0M
Runway
6.9 mo
Revenue
$583K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| eganelisib | Phase 2 |
| xh-s003 | Phase 2 |
Frequently asked questions
How many drug candidates are in INFINITY PHARMACEUTICALS, INC.'s pipeline?
INFINITY PHARMACEUTICALS, INC. (INFI) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is INFINITY PHARMACEUTICALS, INC.'s lead drug candidate?
INFINITY PHARMACEUTICALS, INC.'s most advanced tracked candidate is eganelisib (Phase 2) for solid tumors.
What is INFINITY PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, INFINITY PHARMACEUTICALS, INC. has approximately 6.9 months of cash runway.
Get the full picture on INFINITY PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.